XBI145.88 −3.10%IBB207.98 −2.13%S&P 5007,416.59 −1.92%NASDAQ 10027,197.15 −2.67%DOW 3051,608.17 −1.41%FTSE 10010,803.40 −0.72%
Biotech Today Subscribe

Market Watch · Cancer & Oncology

Moderna’s 25% Plunge Exposes Cancer Vaccine Expectations

Moderna’s cancer vaccine improved melanoma outcomes, but analysts tied its stock plunge to lofty expectations as a regulatory filing approaches.

Rafael Quintero · 3 min read
Moderna’s 25% Plunge Exposes Cancer Vaccine Expectations

Key facts

  • Initial stock reaction: Moderna fell as much as 25% Thursday after partial trial results leaked.
  • Primary clinical result: Vaccine plus Keytruda reduced melanoma recurrence or death risk by 42% versus Keytruda alone.
  • Latest Moderna trade: MRNA: 195.73 (currency unspecified), down 1.57%; Oct. 27, 2026, 15:56:44 GMT.
  • Two-year outcome: About 82% were alive without melanoma recurrence with the combination, versus 70% with Keytruda alone.

Moderna shares fell as much as 25% after a partial data leak, although full trial results showed its cancer vaccine with Merck’s Keytruda reduced the risk of melanoma recurrence or death by 42%.

Moderna (MRNA) shares fell as much as 25% Thursday after partial results from its cancer vaccine trial leaked, exposing the gap between a clinically positive result and the expectations built into its stock. The full results released later that day showed a benefit from adding the personalized treatment to Merck’s (MRK) Keytruda.

The selloff followed a rally of more than 530% in Moderna shares this year through Thursday afternoon. Analysts at BMO Capital Markets and UBS described the results as positive and pointed to elevated investor expectations as a likely explanation for the reaction, according to CNBC Health.

Merck shares fell about 1% Thursday, having gained nearly 41% for the year. In subsequent trading, Moderna was down 1.57% and Merck was up 1.40% on Tuesday, Oct. 27, as of 15:56:44 GMT. Those intraday moves are separate from the initial reaction to the trial disclosure.

What the melanoma results establish

The phase 3 trial tested intismeran autogene, a vaccine tailored to mutations in each patient’s tumor, alongside Keytruda. In certain melanoma patients, the combination reduced the risk of recurrence or death by 42% compared with Keytruda alone. It also reduced the risk of cancer spreading to distant parts of the body or death by 38%.

About 82% of patients receiving the combination were alive without their melanoma returning at two years, compared with 70% receiving Keytruda alone. That measure addresses whether patients remain free of recurrence; it does not establish that the treatment extends overall survival. The companies said it was too early to determine that outcome.

About 82% of patients receiving the combination were alive without their melanoma returning at two years, compared with 70% receiving Keytruda alone.

A separate analysis following the six-month vaccine regimen showed a 58% reduction in recurrence or death risk. That finding should be distinguished from the 42% result rather than treated as a replacement for it: the analyses describe different treatment periods.

Dr. Hussein Tawbi, a trial investigator at the University of Texas MD Anderson Cancer Center, described the findings as a major advance for patients. He said the added benefit came with milder toxicity than other cancer treatments, including side effects such as injection-site pain.

A filing approaches, but manufacturing remains important

Moderna CEO Stéphane Bancel said the company was finishing a regulatory filing aimed at securing full approval in 2027. The results support that effort, but the approval remains a goal rather than an accomplished event.

The personalized approach also creates a practical challenge. Manufacturing can take six weeks because the vaccine targets mutations specific to an individual patient’s tumor. Merck CEO Robert Davis said the company believes it can shorten that timeline, potentially allowing patients to receive treatment sooner.

For Moderna, approval would add a cancer treatment alongside its vaccine portfolio for Covid-19, flu and respiratory syncytial virus. The commercial opportunity therefore depends not only on the clinical benefit but also on obtaining approval and delivering an individually manufactured product.

Other cancers remain a separate test

Merck and Moderna are also studying the vaccine in non-small cell lung cancer, bladder cancer and renal cell carcinoma. UBS analysts said the melanoma results increased their confidence in the kidney and bladder cancer studies.

Those programs are potential extensions, not established uses. Merck Research Laboratories President Dr. Dean Li acknowledged that the companies still need to demonstrate effectiveness across tumor types. For investors, the melanoma results strengthen the vaccine’s clinical case without settling its eventual reach—or whether that reach will justify the expectations behind Moderna’s rally.

Sources

Photo: Los Muertos Crew · Pexels Licence — source

Filed under Market Watch Cancer & Oncology

The Biotech Today briefing

Trials, approvals and the deals moving biotech, in your inbox. Free.

Unsubscribe from any email. See our privacy policy.